Scilex Holding Company Share Price & Technical Analysis
SCLX · $6.41 (+4.91%)
Healthcare / Drug Manufacturers - General
$6.41
+4.91%
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve …
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-42% return in May, 4% avg return in past 3 year May month.
-33% return in 2026, 9% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -30% | -4% | -16% | 59% | -42% | – | – | – | – | – | – | – | -33% |
| 25 | -8% | -39% | 1% | -49% | 9% | 18% | 131% | 37% | 13% | -18% | 23% | -40% | 78% |
| 24 | -20% | 37% | 4% | -46% | 23% | 72% | -16% | -27% | -23% | 6% | -33% | -35% | -57% |
| 23 | 75% | 12% | -6% | -15% | -18% | -7% | -2% | -46% | -48% | 32% | -32% | 59% | 5% |
| 22 | 0% | 0% | 0% | 0% | 0% | 0% | 1% | 0% | 0% | 1% | -57% | -12% | -65% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is based in Palo Alto, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$48.81M
P/E ratio
—
52W high
$34.27
52W low
$4.20
Volume
1,77,721
Beta
1.79
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Scilex Holding Company share price today?
- Scilex Holding Company (SCLX) last traded around $6.41 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SCLX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SCLX. Download the app for real-time alerts.
- How can I analyze Scilex Holding Company stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.